These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22843277)

  • 1. A designer drug for amyloid polyneuropathy.
    Chalk C
    Neurology; 2012 Aug; 79(8):730-1. PubMed ID: 22843277
    [No Abstract]   [Full Text] [Related]  

  • 2. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

  • 3. Is it better than it seems or just good enough? The tafamidis saga.
    de Carvalho M
    Muscle Nerve; 2012 Dec; 46(6):839-40. PubMed ID: 23042137
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 5. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
    Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
    Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
    Castro J; Costa J; de Castro I; Conceição I
    Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Baldovino S; Costanzo P; Roccatello D
    Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
    [No Abstract]   [Full Text] [Related]  

  • 12. Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Elliott P; Gundapaneni B; Sultan MB
    Circ Heart Fail; 2022 Jul; 15(7):e009637. PubMed ID: 35748240
    [No Abstract]   [Full Text] [Related]  

  • 13. Significant reduction in proteinuria after treatment with tafamidis.
    Ferrer-Nadal A; Ripoll T; Uson M; Figuerola A; Andreu H; Losada I; Gonzalez J; Cisneros-Barroso E; Buades J
    Amyloid; 2019; 26(sup1):67-68. PubMed ID: 31343359
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis in hereditary ATTR amyloidosis - our experience on monitoring the ocular manifestations.
    Casal I; Monteiro S; Beirão JM
    Amyloid; 2016 Dec; 23(4):262-263. PubMed ID: 27748624
    [No Abstract]   [Full Text] [Related]  

  • 16. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations.
    Cárdenas-Soto K; Torres-Octavo B; Mendoza-Tejeda C; Fueyo-Rodríguez O; Domínguez-Rico C; Gonzalez-Duarte A
    Amyloid; 2019; 26(sup1):57-58. PubMed ID: 31343329
    [No Abstract]   [Full Text] [Related]  

  • 18. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
    Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
    Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance.
    Ishii T; Sekijima Y; Ando Y
    Amyloid; 2019; 26(sup1):45-46. PubMed ID: 31343289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.